保健衛生学部 リハビリテーション学科

亀井 浩行|

カメイ ヒロユキ  (Hiroyuki Kamei)

基本情報

所属
名城大学 薬学部 教授 (professor, Dr.)
藤田医科大学 客員講師
名古屋大学 客員研究員
学位
薬学博士(名城大学)

通称等の別名
ひろ
研究者番号
60345593
J-GLOBAL ID
201801021025170496
researchmap会員ID
B000299827

学歴

 3

論文

 183
  • Yuma Shimizu, Junichi Miyaura, Manako Hanya, Masahide Okuda, Hiroaki Mizutani, Hiroyuki Kamei
    Journal of Pharmaceutical Health Care and Sciences 12(1) 2026年5月16日  査読有り責任著者
    Abstract Background Even after alcohol detoxification, 50–80% of patients with alcohol use disorder (AUD) exhibit cognitive impairments, which affect key domains of social functioning, such as employment, interpersonal relationships, and communication. Therefore, it is necessary to assess cognitive function in patients with AUD in routine practice. However, existing cognitive function assessments are difficult to apply in routine practice because they require a long time, are burdensome on patients, and are limited to evaluators with special training. The present study investigated the relationship between a simple and novel assessment, called Psychomotor Function Tests (PFT), and existing Neuropsychological Tests (NT) in patients with AUD. Methods Twenty patients with AUD underwent a cognitive assessment using NT (Raven’s Colored Progressive Matrices, Frontal Assessment Battery (FAB), and Clinical Assessment for Attention (CAT)) as well as tablet-based PFT, with each assessment being conducted twice: 1 week and 2 months after alcohol detoxification with benzodiazepines. Twenty healthy controls underwent the same assessment. Results Psychomotor function assessed by PFT was significantly worse in patients with AUD than in healthy controls ( p  < 0.05). At both assessment time points, PFT composite score correlated with the total FAB score ( r  = 0.500, 0.458) and CAT time required ( r = -0.447, -0.496). The CRT, CTT-TT, CTT-PAT and RVIP demonstrated a degree of test-retest reliability ( r  = 0.816, 0.812, 0.797, 0.676). Conclusions The correlations observed between PFT and conventional NT suggest the utility of PFT for evaluating cognitive function in patients with AUD in clinical settings.
  • Yuma Shimizu, Ippei Takeuchi, Manako Hanya, Kiyoshi Fujita, Hiroyuki Kamei
    Heliyon 11(17) e44179-e44179 2025年12月  査読有り責任著者
  • Yuma Shimizu, Ippei Takeuchi, Masakazu Hatano, Manako Hanya, Kiyoshi Fujita, Nakao Iwata, Hiroyuki Kamei
    Schizophrenia Research: Cognition 42 100390-100390 2025年12月  査読有り責任著者
  • 清水 侑真, 竹内 一平, 波多野 正和, 半谷 眞七子, 藤田 潔, 岩田 仲生, 亀井 浩行
    日本精神薬学会総会・学術集会プログラム・抄録集 9回 100-100 2025年9月  
  • 神谷 美名, 清水 侑真, 竹内 一平, 波多野 正和, 半谷 眞七子, 藤田 潔, 岩田 仲生, 亀井 浩行
    日本精神薬学会総会・学術集会プログラム・抄録集 9回 100-100 2025年9月  

MISC

 179

書籍等出版物

 5

講演・口頭発表等

 64

担当経験のある科目(授業)

 4

共同研究・競争的資金等の研究課題

 5